4-epidoxorubicin in recurrent cervical cancer.
Thirty-eight patients with histologically proven recurrent cervical cancer were treated with epirubicin, an analogue of anthracycline. There were eight complete responders and ten partial responders. The overall response rate was 47.8%. The survival duration of the responders was significantly longer than that of the nonresponders. The optimal dose of epirubicin has yet to be determined. The dosage of 120 mg/m2 was well tolerated. The role of epirubicin as an adjuvant chemotherapeutic agent in the treatment of cervical cancer was discussed.
Wong
L C
LC
Department of Obstetrics and Gynaecology, University of Hong Kong.
Choy
D T
DT
Ngan
H Y
HY
Sham
J S
JS
Ma
H K
HK
D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D015251:Epirubicin